Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Abstract Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications. We aimed to estimate the cost-effectiveness of sorafenib and...

Full description

Bibliographic Details
Main Authors: Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Sorafenib
Transarterial chemoembolization
Advanced-stage hepatocellular carcinoma
Cost-effectiveness analysis
Markov model
Online Access:http://link.springer.com/article/10.1186/s12885-018-4308-7

Internet

http://link.springer.com/article/10.1186/s12885-018-4308-7

Similar Items